High-risk EBV promotes immune evasion in nasopharyngeal carcinoma by upregulating HLA-DP via the encoded BALF2-HR variant - PubMed
6 hours ago
- #EBV
- #Nasopharyngeal Carcinoma
- #Immune Evasion
- High-risk Epstein-Barr virus (EBV) variant BALF2-HR upregulates HLA class II molecules, particularly HLA-DP, in nasopharyngeal carcinoma (NPC).
- Upregulated HLA-DP interacts with LAG-3 on CD8+ T cells, causing T cell exhaustion, inhibiting cytokine secretion, and promoting immune evasion, reducing anti-PD-1 therapy efficacy.
- BALF2-HR enhances HLA-DP transcription by binding to KPNA2 and facilitating nuclear translocation of CIITA.
- Combination immunotherapy using anti-LAG-3 and anti-PD-1 antibodies significantly improves NPC treatment outcomes.